[Combined drug/hormone therapy in metastatic breast cancer with vincristine, adriamycin, cyclophosphamide and high dose medroxyprogesterone acetate--VAC-MAP. Preliminary results of a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
In a study of the AIO 67 patients with metastatic breast cancer were treated with VAC-MAP--a combination of chemo- and hormonal therapy consisting of vincristine 1 mg/m2 day 1, i.v.; adriamycin 40 mg/m2 day 1, i.v.; cyclophosphamide 200 mg/m2 day, 3-6, p.o. and medroxyprogesteroneacetate 1500 mg daily (day 1-42), 500 mg daily from day 42 until relapse. At present, 50 patients are evaluable. Remission rates of all patients correspond with those described in the literature for VAC, i.e. 58%. In CMF-resistant cases remissions were obtained in 50% of the patients and even 78.6% in hormone receptor positive tumors. Only 2 patients did not respond to the therapy. It appears that with a maintenance therapy of 500 mg MAP daily remission duration cannot be prolonged, apparently due to too low a dosage. MAP should improve the subjective tolerance of chemotherapy and bone marrow tolerance towards cytostatic drugs.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D009362:Neoplasm Metastasis; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D008525:Medroxyprogesterone
Kombinierte Chemo-/Hormontherapie beim metastasierenden Mammakarzinom mit Vincristin, Adriamycin, Cyclophosphamid und hochdosiertem Medroxyprogesteronacetat--VAC-MAP. Zwischenergebnisse einer Phase-II-Studie der AIO (Arbeitsgemeinschaft für internistische Onkologie der Deutschen Krebsgesellschaft).